

- metastasis of pancreatic ductal adenocarcinoma. *Exp Mol Med* 2014;46:e117.
108. Subramani R, Nandy SB, Pedroza DA, Lakshmanaswamy R. Role of growth hormone in breast cancer. *Endocrinology* 2017;158:1543-55.
 109. Kaulsay KK, Mertani HC, Törnell J, Morel G, Lee KO, et al. Autocrine stimulation of human mammary carcinoma cell proliferation by human growth hormone. *Exp Cell Res* 1999;250:35-50.
 110. Mertani HC, Zhu T, Goh EL, Lee KO, Morel G, et al. Autocrine human growth hormone (hGH) regulation of human mammary carcinoma cell gene expression. Identification of CHOP as a mediator of hGH-stimulated human mammary carcinoma cell survival. *J Biol Chem* 2001;276:21464-75.
 111. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. *J Clin Invest* 2009;119:1420-8.
 112. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. *Nat Rev Mol Cell Biol* 2014;15:178-96.
 113. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. *Oncogene* 2010;29:4741-51.
 114. Du B, Shim J. Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. *Molecules* 2016;21:965.
 115. Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. *Genes Dev* 2013;27:2192-206.
 116. Mitra A, Mishra L, Li S. EMT, CTCs and CSCs in tumor relapse and drug-resistance. *Oncotarget* 2015;6:10697-711.
 117. Kong D, Li Y, Wang Z, Sarkar F. Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins? *Cancers (Basel)* 2011;3:716-29.
 118. Aiello NM, Brabletz T, Kang Y, Nieto MA, Weinberg RA, et al. Upholding a role for EMT in pancreatic cancer metastasis. *Nature* 2017;547:E7-8.
 119. Fischer KR, Durrans A, Lee S, Sheng J, Li F, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. *Nature* 2015;527:472-6.
 120. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. *Stem Cells* 2009;27:2059-68.
 121. Yang H, Zhang G, Che X, Yu S. Slug inhibition increases radiosensitivity of nasopharyngeal carcinoma cell line C666-1. *Exp Ther Med* 2018;15:3477-82.
 122. Pulkka OP, Nilsson B, Sarlomo-Rikala M, Reichardt P, Eriksson M, et al. SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour. *Br J Cancer* 2017;116:1195-202.
 123. Yochum ZA, Socinski MA, Burns TF. Paradoxical functions of ZEB1 in EGFR-mutant lung cancer: tumor suppressor and driver of therapeutic resistance. *J Thorac Dis* 2016;8:E1528-31.
 124. Yochum ZA, Cades J, Wang H, Chatterjee S, Simons BW, et al. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. *Oncogene* 2019;38:656-70.
 125. Mukhina S, Mertani HC, Guo K, Lee KO, Gluckman PD, et al. Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. *Proc Natl Acad Sci U S A* 2004;101:15166-71.
 126. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. *Cancer Metastasis Rev* 2009;28:15-33.
 127. Aiello NM, Maddipati R, Norgard RJ, Balli D, Li J, et al. EMT subtype influences epithelial plasticity and mode of cell migration. *Dev Cell* 2018;45:681-95.e4.
 128. Zhang X, Zhu T, Chen Y, Mertani HC, Lee KO, et al. Human growth hormone-regulated HOXA1 is a human mammary epithelial oncogene. *J Biol Chem* 2003;278:7580-90.
 129. Zhu T, Starling-Emerald B, Zhang X, Lee KO, Gluckman PD, et al. Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. *Cancer Res* 2005;65:317-24.
 130. Shafiei F, Rahnama F, Pawella L, Mitchell MD, Gluckman PD, et al. DNMT3A and DNMT3B mediate autocrine hGH repression of plakoglobin gene transcription and consequent phenotypic conversion of mammary carcinoma cells. *Oncogene* 2008;27:2602-12.
 131. Wang JJ, Chong QY, Sun XB, You ML, Pandey V, et al. Autocrine hGH stimulates oncogenicity, epithelial-mesenchymal transition and cancer stem cell-like behavior in human colorectal carcinoma. *Oncotarget* 2017;8.
 132. Basu R, Wu S, Kopchick J. Targeting growth hormone receptor in human melanoma cells attenuates tumor progression and epithelial mesenchymal transition via suppression of multiple oncogenic pathways. *Oncotarget* 2017;5.
 133. Pandey V, Perry JK, Mohankumar KM, Kong XJ, Liu SM, et al. Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. *Endocrinology* 2008;149:3909-19.
 134. Chen Z, Shi T, Zhang L, Zhu P, Deng M, et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. *Cancer Lett* 2016;370:153-64.
 135. Montanari F, Ecker GF. Prediction of drug-ABC-transporter interaction - recent advances and future challenges. *Adv Drug Deliv Rev* 2015;86:17-26.
 136. Heimerl S, Bosserhoff AK, Langmann T, Ecker J, Schmitz G. Mapping ATP-binding cassette transporter gene expression profiles in melanocytes and melanoma cells. *Melanoma Res* 2007;17:265-73.
 137. Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. *Nat Rev Cancer* 2018;18:452-64.
 138. Kathawala RJ, Gupta P, Ashby CR, Chen ZS. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. *Drug Resist Updat* 2015;18:1-17.
 139. Szakács G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, et al. Predicting drug sensitivity and resistance. *Cancer Cell* 2004;6:129-37.

140. Dvorak P, Pesta M, Soucek P. ABC gene expression profiles have clinical importance and possibly form a new hallmark of cancer. *Tumor Biol* 2017;39:101042831769980.
141. Choi CH. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. *Cancer Cell Int* 2005;5:30.
142. Ejendal KFK, Hrycyna CA. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. *Curr Protein Pept Sci* 2002;3:503-11.
143. Jaramillo AC, Al Saig F, Cloos J, Jansen G, Peters GJ. How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance? *Cancer Drug Resist* 2018;1:6-29.
144. Chen KG, Valencia JC, Gillet JP, Hearing VJ, Gottesman MM. Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. *Pigment Cell Melanoma Res* 2009;22:740-9.
145. Chen KG, Valencia JC, Lai B, Zhang G, Paterson JK, et al. Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. *Proc Natl Acad Sci* 2006;103:9903-7.
146. Bougen NM, Yang T, Chen H, Lobie PE, Perry JK. Autocrine human growth hormone reduces mammary and endometrial carcinoma cell sensitivity to mitomycin C. *Oncol Rep* 2011;26:487-93.
147. Holtz AN, Yee D, Beckwith H. Abstract 5839: growth hormone receptor (GHR) expression confers resistance to ruxolitinib in endocrine-resistant breast cancer cells. *Cancer Res* 2018;78:5839.
148. Basu R, Baumgaertel N, Wu S, Kopchick JJ. Growth hormone receptor knockdown sensitizes human melanoma cells to chemotherapy by attenuating expression of ABC drug efflux pumps. *Horm Cancer* 2017;8:143-56.
149. Arumugam A, Subramani R, Nandy SB, Terreros D, Dwivedi AK, et al. Silencing growth hormone receptor inhibits estrogen receptor negative breast cancer through ATP-binding cassette sub-family G member 2. *Exp Mol Med* 2019;51:2.
150. Wu AML, Dalvi P, Lu X, Yang M, Riddick DS, et al. Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells. *Mol Pharmacol* 2013;83:377-88.
151. Santisteban M. ABC transporters as molecular effectors of pancreatic oncogenic pathways: the hedgehog-GLI model. *J Gastrointest Cancer* 2010;41:153-8.
152. Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. *Nat Rev Cancer* 2010;10:147-56.
153. Pahnke J, Langer O, Krohn M. Alzheimer's and ABC transporters - new opportunities for diagnostics and treatment. *Neurobiol Dis* 2014;72:54-60.
154. Abuznait AH, Kaddoumi A. Role of ABC transporters in the pathogenesis of Alzheimer's disease. *ACS Chem Neurosci* 2012;3:820-31.
155. Mahringer A, Fricker G. ABC transporters at the blood-brain barrier. *Expert Opin Drug Metab Toxicol* 2016;12:499-508.
156. Tarling EJ, de Aguiar Vallim TQ, Edwards PA. Role of ABC transporters in lipid transport and human disease. *Trends Endocrinol Metab* 2013;24:342-50.
157. Schumacher T, Benndorf RA. ABC transport proteins in cardiovascular disease-a brief summary. *Molecules* 2017;22.
158. Gottesman MM, Ambudkar SV. Overview: ABC transporters and human disease. *J Bioenerg Biomembr* 2001;33:453-8.
159. Stanton B. ABC transporters in liver, kidney, and intestine. *Kidney Int* 2002;62:1520-1.
160. Stefková J, Poledne R, Hubáček JA. ATP-binding cassette (ABC) transporters in human metabolism and diseases. *Physiol Res* 2004;53:235-43.
161. Battle E, Clevers H. Cancer stem cells revisited. *Nat Med* 2017;23:1124-34.
162. Ciurea ME, Georgescu AM, Purcaru SO, Artene SA, Emami GH, et al. Cancer stem cells: biological functions and therapeutically targeting. *Int J Mol Sci* 2014;15:8169-85.
163. Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. *Stem Cells Int* 2018;2018:1-16.
164. Florea V, Majid SS, Kanashiro-Takeuchi RM, Cai RZ, Block NL, et al. Agonists of growth hormone-releasing hormone stimulate self-renewal of cardiac stem cells and promote their survival. *Proc Natl Acad Sci* 2014;111:17260-5.
165. Sackmann-Sala L, Guidotti JE, Goffin V. Minireview: prolactin regulation of adult stem cells. *Mol Endocrinol* 2015;29:667-81.
166. Sackmann-Sala L, Goffin V. Prolactin-induced prostate tumorigenesis. *Adv Exp Med Biol* 2015;846:221-42.
167. Neradugomma NK, Subramaniam D, Tawfik OW, Goffin V, Kumar TR, et al. Prolactin signaling enhances colon cancer stemness by modulating Notch signaling in a Jak2-STAT3/ERK manner. *Carcinogenesis* 2014;35:795-806.
168. Chen YJ, Zhang X, Wu ZS, Wang JJ, Lau AYC, et al. Autocrine human growth hormone stimulates the tumor initiating capacity and metastasis of estrogen receptor-negative mammary carcinoma cells. *Cancer Lett* 2015;365:182-9.
169. Lombardi S, Honeth G, Ginestier C, Shinomiya I, Marlow R, et al. Growth hormone is secreted by normal breast epithelium upon progesterone stimulation and increases proliferation of stem/progenitor cells. *Stem Cell Reports* 2014;2:780-93.
170. Chen YJ, You ML, Chong QY, Pandey V, Zhuang QS, et al. Autocrine human growth hormone promotes invasive and cancer stem cell-like behavior of hepatocellular carcinoma cells by STAT3 dependent inhibition of CLAUDIN-1 expression. *Int J Mol Sci* 2017;18:1274.
171. Chen HHW, Kuo MT. Improving radiotherapy in cancer treatment: Promises and challenges. *Oncotarget* 2017;8:62742-58.
172. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. *Int J Med Sci* 2012;9:193-9.
173. Kim BM, Hong Y, Lee S, Liu P, Lim JH, et al. Therapeutic implications for overcoming radiation resistance in cancer therapy. *Int J Mol Sci* 2015;16:26880-913.
174. Barker HE, Paget JTE, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. *Nat Rev Cancer* 2015;15:409-25.

175. Willers H, Azzoli CG, Santivasi WL, Xia F. Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer. *Cancer J* 2013;19:200-7.
176. Redelman D, Welniak LA, Taub D, Murphy WJ. Neuroendocrine hormones such as growth hormone and prolactin are integral members of the immunological cytokine network. *Cell Immunol* 252:111-21.
177. Bougen NM, Steiner M, Pertziger M, Banerjee A, Brunet-Dunand SE, et al. Autocrine human GH promotes radioresistance in mammary and endometrial carcinoma cells. *Endocr Relat Cancer* 2012;19:625-44.
178. Prieto I, Gómez de Segura IA, García Grande A, García P, Carralero I, et al. Morphometric and proliferative effects of growth hormone on radiation enteritis in the rat. *Rev Esp Enferm Dig* 1998;90:163-73.
179. Lempereur L, Brambilla D, Maria Scoto G, D'Alcama M, Goffin V, et al. Growth hormone protects human lymphocytes from irradiation-induced cell death. *Br J Pharmacol* 2003;138:1411-6.
180. Morante J, Vallejo-Cremades MT, Gómez-García L, Vázquez I, Gómez-de-Segura IA, et al. Differential action of growth hormone in irradiated tumoral and nontumoral intestinal tissue. *Dig Dis Sci* 2003;48:2159-66.
181. Caz V, Elvira M, Tabernero M, Grande AG, Lopez-Plaza B, et al. Growth hormone protects the intestine preserving radiotherapy efficacy on tumors: a short-term study. *PLoS One* 2015;10:e0144537.
182. Chen BJ, Deoliveira D, Spasojevic I, Sempowski GD, Jiang C, et al. Growth hormone mitigates against lethal irradiation and enhances hematologic and immune recovery in mice and nonhuman primates. *PLoS One* 2010;5:e11056.
183. Zhou D, Deoliveira D, Kang Y, Choi SS, Li Z, et al. Insulin-like growth factor 1 mitigates hematopoietic toxicity after lethal total body irradiation. *Int J Radiat Oncol Biol Phys* 2013;85:1141-8.
184. Wu XY, Chen C, Yao XQ, Cao QH, Xu Z, et al. Growth hormone protects colorectal cancer cells from radiation by improving the ability of DNA damage repair. *Mol Med Rep* 2014;10:486-90.
185. Evans A, Jamieson SMF, Liu DX, Wilson WR, Perry JK. Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model. *Cancer Lett* 2016;379:117-23.
186. Wu X, Wan M, Li G, Xu Z, Chen C, et al. Growth hormone receptor overexpression predicts response of rectal cancers to pre-operative radiotherapy. *Eur J Cancer* 2006;42:888-94.
187. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. *Nat Rev Mol Cell Biol* 2014;15:786-801.
188. Burnier J V, Wang N, Michel RP, Hassanain M, Li S, et al. Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis. *Oncogene* 2011;30:3766-83.
189. Jenkins MH, Croteau W, Mullins DW, Brinckerhoff CE. The BRAFV600E inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells. *Matrix Biol* 2015;48:66-77.
190. Fang M, Yuan J, Peng C, Li Y. Collagen as a double-edged sword in tumor progression. *Tumor Biol* 2014;35:2871-82.
191. Rizwan A, Bulte C, Kalaichelvan A, Cheng M, Krishnamachary B, et al. Metastatic breast cancer cells in lymph nodes increase nodal collagen density. *Sci Rep* 2015;5:10002.
192. Gao H, Chakraborty G, Zhang Z, Akalay I, Gadiya M, et al. Multi-organ site metastatic reactivation mediated by non-canonical discoidin domain receptor 1 signaling. *Cell* 2016;166:47-62.
193. Januchowski R, Świerczewska M, Sterzyńska K, Wojtowicz K, Nowicki M, et al. Increased expression of several collagen genes is associated with drug resistance in ovarian cancer cell lines. *J Cancer* 2016;7:1295-310.
194. Doessing S, Heinemeier KM, Holm L, Mackey AL, Schjerling P, et al. Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis. *J Physiol* 2010;588:341-51.
195. An X, Sarmiento C, Tan T, Zhu H. Regulation of multidrug resistance by microRNAs in anti-cancer therapy. *Acta Pharm Sin B* 2017;7:38-51.
196. Zhang W, Qian P, Zhang X, Zhang M, Wang H, et al. Autocrine/paracrine human growth hormone-stimulated microRNA 96-182-183 cluster promotes epithelial-mesenchymal transition and invasion in breast cancer. *J Biol Chem* 2015;290:13812-29.
197. Ma Y, Liang AJ, Fan YP, Huang YR, Zhao XM, et al. Dysregulation and functional roles of miR-183-96-182 cluster in cancer cell proliferation, invasion and metastasis. *Oncotarget* 2016;7:42805-25.
198. Hao P, Waxman DJ. Functional roles of sex-biased, growth hormone-regulated microRNAs miR-1948 and miR-802 in young adult mouse liver. *Endocrinology* 2018;159:1377-92.
199. Wang D, Lu G, Shao Y, Xu D. microRNA-802 inhibits epithelial-mesenchymal transition through targeting flotillin-2 in human prostate cancer. *Biosci Rep* 2017;37.
200. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. *Oncogene* 2006;25:1679-91.
201. Bruno RD, Njar VCO. Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. *Bioorg Med Chem* 2007;15:5047-60.
202. Waxman DJ, Ram PA, Pampori NA, Shapiro BH. Growth hormone regulation of male-specific rat liver P450s 2A2 and 3A2: induction by intermittent growth hormone pulses in male but not female rats rendered growth hormone deficient by neonatal monosodium glutamate. *Mol Pharmacol* 1995;48:790-7.
203. Cheung NW, Liddle C, Coverdale S, Lou JC, Boyages SC. Growth hormone treatment increases cytochrome P450-mediated antipyrine clearance in man. *J Clin Endocrinol Metab* 1996;81:1999-2001.
204. Gil Berglund E, Johannsson G, Beck O, Bengtsson BA, Rane A. Growth hormone replacement therapy induces codeine clearance. *Eur J Clin Invest* 2002;32:507-12.
205. Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. *CA Cancer J Clin* 2017;67:326-44.
206. Pouncey AL, Scott AJ, Alexander JL, Marchesi J, Kinross J. Gut microbiota, chemotherapy and the host: the influence of the gut

- microbiota on cancer treatment. *Ecancermedalscience* 2018;12:868.
207. Fessler JL, Gajewski TF. The microbiota: a new variable impacting cancer treatment outcomes. *Clin Cancer Res* 2017;23:3229-31.
 208. De Almeida CV, de Camargo MR, Russo E, Amedei A. Role of diet and gut microbiota on colorectal cancer immunomodulation. *World J Gastroenterol* 2018;25:151-62.
 209. Rea D, Coppola G, Palma G, Barbieri A, Luciano A, et al. Microbiota effects on cancer: from risks to therapies. *Oncotarget* 2018;9.
 210. Yan J, Charles JF. Gut Microbiota and IGF-1. *Calcif Tissue Int* 2018;102:406-14.
 211. Friend KE. Cancer and the potential place for growth hormone receptor antagonist therapy. *Growth Horm IGF Res* 2001;11:S121-3.
 212. Leporati P, Fonte R, de Martinis L, Zambelli A, Magri F, et al. A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression. *BMC Cancer* 2015;15:397.
 213. Telleria CM. Drug repurposing for cancer therapy. *J Cancer Sci Ther* 2012;4:ix-xi.
 214. Langdon CG, Platt JT, Means RE, Iyidogan P, Mamillapalli R, et al. Combinatorial screening of pancreatic adenocarcinoma reveals sensitivity to drug combinations including bromodomain inhibitor plus neddylation inhibitor. *Mol Cancer Ther* 2017;16:1041-53.
 215. Nosengo N. Can you teach old drugs new tricks? *Nature* 2016;534:314-6.
 216. Wu XY, Chen C, Yao XQ, Cao QH, Xu Z, et al. Growth hormone protects colorectal cancer cells from radiation by improving the ability of DNA damage repair. *Mol Med Rep* 2014;10:486-90.